摘要
目的探讨小细胞肺癌(SCLC)骨髓转移的临床特征、治疗方法及预后影响因素。方法回顾性分析29例SCLC骨髓转移病例的临床资料,应用SPSS10.0软件包分析其预后影响因素。结果29例SCLC患者中位年龄为52岁。诊断为局限期(LD)11例,广泛期(ED)18例。出现临床症状到确诊为SCLC的中位时间是2个月,诊断SCLC后到确诊骨髓转移的中位时间是20天。全组患者中位生存期为6个月(2～19个月),确诊骨髓转移后中位生存期为5个月(10天～18个月)。患者生存期与临床分期、发病部位、转移部位数目、含铂类化疗方案及骨髓缓解无关。采用含足叶乙甙(VP16)的化疗方案、联合放疗与患者生存期密切相关。结论SCLC骨髓转移后生存期短,治疗仍以化疗为主的综合治疗。采用含VP16的化疗方案、联合放疗对SCLC骨髓转移的预后较好。
Objective To evaluate the clinical characteristics,treatment and prognostic factors for patients with bone marrow metastases from small cell lung cancer(SCLC).Methods The clinical data of 29 cases with bone marrow metastases from SCLC were retrospectively analyzed by statistic software package of SPSS 10.0 for prognostic factors.Results The median age was 52 years old.There were 11 patients with local disease(LD) and 18 patients with extend disease(ED).The median time it took to document the diagnosis of SCLC after they had symptoms was 2 months.The median time it took to demonstrate the bone marrow metastases after the diagnosis of SCLC was 20 days.The median survival time was 6 months(range:2～19 months) for patients with documented SCLC and 5 months(range:10 days～18 months) for patient with documented bone marrow metastases.Clinical stage,the site of lesions,the numbers of involved organs,platinum-containing chemotherapy regimens and remission of bone marrow metastases had no significant correlation with survival time.Etoposide-containing regimens and combined radiotherapy had a close relation with the survival time.Conclusion Survival time of patients who have bone marrow metastases from SCLC is short.It should be treated with chemotherapy,as well as other combined methods.The prognostic factors include etoposide-containing regimens and combined radiotherapy.
出处
《实用癌症杂志》
2004年第6期609-611,共3页
The Practical Journal of Cancer
关键词
小细胞肺癌
骨髓转移
临床分析
预后
治疗
Small cell lung cancer(SCLC)
Bone marrow metastasis
Clinical analysis
Prognosis
